Cohort Company News - MedTech Innovator

Western Ireland’s University Hospital Galway Leading Advanced Heart Failure Monitoring Clinical Trial

DateJun 06 2020

The investigational product, known as the Cordella Sensor from U.S.-based company called Endotronix, detects changes in the health of patients with heart failure while securely transmitting information to the cardiovascular team. With this data in real time, the cardiovascular team can not only receive relevant updates but also can intervene with the goal of preventing heart failure flare-up resulting in emergency hospitalization.

LabCorp Launches Website to Connect Patients with COVID-19 Clinical Trials

DateJun 03 2020

LabCorp also announced that it is partnering with digital clinical trial software maker Medable to allow clinical trial participants to engage with trials remotely. This is expected to help with remote data collection, patient engagement and easier app access for trials.

Bigfoot Biomedical raises $55m in Series C

DateJun 03 2020

Milpitas, Calif.-based Bigfoot said in a news release that the proceeds will support product development and the regulatory pathway for its Bigfoot Unity system as a part of the Bigfoot Unity Diabetes Management Program.

Fibralign Announces Strategic Partnership With Terumo

DateJun 02 2020

Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema.

Rhaeos, Inc. Receives FDA Breakthrough Device Designation for FlowSense™ Noninvasive Thermal Sensor

DateJun 01 2020

The Breakthrough Device Designation is supported by data from several recently published studies demonstrating effective use of FlowSense in detecting changes in cerebrospinal fluid volume and flow. By receiving this designation, Rhaeos will work in close collaboration with the FDA to streamline the market clearance process of FlowSense for this high-risk patient population.

Arterys Raises $28 Million to Accelerate the Delivery of Medical AI to Practices Around the World

DateMay 29 2020

"The current crisis has shown us the necessity of a different approach to providing healthcare, where technology and AI are crucial for future success. Arterys is committed to transforming the way AI is integrated into the medical workflow, a promise that is long due in the industry. We recently launched our cloud platform and marketplace that will consolidate the work of thousands of AI models to be readily available for use by healthcare institutions around the globe," said Henry Weinstein, Managing Partner at Benslie International Ltd.

PercuSense Secures DoD Funds for Chemical Exposure Monitoring Tech Dev’t

DateMay 29 2020

The company said Thursday it will use the funds awarded by the Defense Innovation Unit and the Defense Threat Reduction Agency to produce the on-body platform for first responders and military personnel to receive exposure alerts in real time.

Medtech Startup Promaxo Raises First Tranche of Series B-1 Funding

DateMay 28 2020

Promaxo, an Oakland-based medical technology startup developing the portable single-sided MRI, today announced that it has raised the first tranche of Series B-1 funding. The equity round was led by Kineticos Disruptor Fund with participation from existing investors. Launched in 2016, Promaxo plans to revolutionize healthcare with its MR imaging and robotic platform.

Neural Analytics aims robotic transcranial doppler at COVID-19 patients

DateMay 28 2020

Doctors are reporting a proliferation of dangerous blood clots in the lungs and other major organs of COVID-19 patients, raising the risk of stroke and other life-threatening complications. While anticoagulant medications can reduce that risk, patients need careful monitoring to ensure their blood is neither too thick nor too thin. To that end, Los Angeles-based startup Neural Analytics Inc. is deploying its robotically assisted transcranial doppler (TCD) system for real-time identification of blood clots and disruptions in blood flow to the brain.

FDA greenlights ICU AI for predicting fatal COVID-19 complications

DateMay 28 2020

The company’s CLEWICU artificial intelligence software ingests a large range of patient data by linking to electronic medical records, connected medical devices and vital sign monitors, with no need for additional data entry by ICU staff. The FDA also said the standalone CLEWICU software, based within the hospital or in the cloud, could help reduce contact between healthcare workers and COVID-19 patients through remote monitoring.

Bardy Diagnostics® Announces CE Mark Certification for 14-Day Carnation® Ambulatory Monitor (CAM®) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis

DateMay 26 2020

"CE marking of the 14-Day CAM patch is a significant corporate milestone and a testament to the quality of the CAM patch and BardyDx's compliance with all applicable European health, safety, performance and environmental requirements," said Ed Vertatschitsch, Chief Operating Officer.

Alleviant Medical completes $6.5m offering

DateMay 19 2020

Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction.

PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology

DateMay 19 2020

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.

PyrAmes Is Granted Breakthrough Device Designation for Boppli, a Continuous, Non-Invasive Blood Pressure Monitoring System

DateMay 18 2020

Breakthrough Device Designation has the potential to accelerate our plans to bring Boppli to market to improve medical care for babies in need of better blood pressure monitoring.

Houston’s Allotrope Medical wins 2020 Texas A&M New Ventures Competition

DateMay 14 2020

Dr. Albert Huang’s company Allotrope Medical took home the top $50,000 prize for the StimSite technology, which is a smooth muscle stimulation technology that allows surgeons to rapidly and safely identify critical tissue structures, like the ureter, during surgery.

Day Zero Diagnostics wins $6.2m from accelerator

DateMay 12 2020

Boston-based Day Zero said in a news release that its system helps offer the most effective antibiotic treatment on the first day that patients are admitted to the hospital, rather than having them undergo multiple days of toxic broad-spectrum antibiotics to prevent septic shock.

Genetesis lands strategic investment to close $9.2M Series B

DateMay 08 2020

Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFluxTM imaging, today announced several important updates. The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. The round included participation by return investors CincyTech, Ohio Innovation Fund and Mark Cuban.

Antibody testing for COVID-19 prepares for its closeup in bid to ease pandemic restrictions

DateMay 07 2020

San Diego-based Abreos Biosciences Inc. is looking to create a multiplex test that goes beyond the simple yes/no COVID-19 antibody results and measures the “specific flavors” of antibodies to provide a more complete picture of the antibodies in a person’s blood.

Louisville medical device company gets emergency FDA approval

DateMay 05 2020

Louisville-based Liberate Medical LLC received an emergency use authorization from the Food and Drug Administration to market its core product, VentFree, during the coronavirus crisis, Louisville Business First reports. VentFree aims to prevent breathing muscles from degrading while patients are on a ventilator.

Medable Secures $25M Funding To Reduce Clinical Trial Timelines

DateMay 04 2020

“The continued participation in clinical trials is important right now,” Medable co-founder and CEO Michelle Longmire, M.D., told Crunchbase News. “Prior to COVID, decentralized clinical trials were a novel, innovative approach. Now that clinics are shut down, decentralized clinical trials are the only approach to continued clinical trials, especially for finding a COVID vaccine. We are the only tech company to be able to provide this service, and we had to make sure we had the capital to execute this platform.”